Clinical Trial Update: hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating hAESCs to prevent acute graft-versus-host disease after hematopoietic stem cell transplantation has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• hAESCs (human amniotic epithelial stem cells)

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Acute Graft Versus Host Disease | Phase 1 | Status: WITHDRAWN